Reported Earlier, Insulet's Omnipod 5 System Proves Effective in Type 2 Diabetes Management
Reported Earlier, Insulet's Omnipod 5 System Proves Effective in Type 2 Diabetes Management
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today shared positive results from its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) type 2 diabetes pivotal trial at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida. This landmark study evaluated the impact of AID in a diverse group of people with type 2 diabetes who require insulin.
全球领先的无管胰岛素泵技术公司银休特（Insulet or the Company）的Omnipod品牌产品，今天在美国糖尿病协会（ADA）第84届科学会议上公布了其Omnipod 5自动胰岛素输送系统（Omnipod 5）的2型糖尿病关键试验的积极结果。这项具有里程碑意义的研究评估了对需要胰岛素的不同人群的AID的影响。
The SECURE-T2D pivotal trial results showed glycemic improvements with the use of Omnipod 5 compared with prior treatment of insulin injections or pump therapy in adults with type 2 diabetes. The study results showed significant reductions in HbA1c, time in hyperglycemia, and total daily insulin dose, and a large improvement in time in range (TIR), without increasing time in hypoglycemia. The study also demonstrated a clinically meaningful improvement in diabetes distress.
SECURE-T2D关键试验结果显示，与2型糖尿病成人之前治疗的胰岛素注射或泵疗法相比，使用Omnipod 5能改善血糖控制。该研究结果表明，在不增加低血糖时间的情况下，HbA1c、高血糖时间和每日总胰岛素剂量均有显著降低，范围内时间（TIR）显著提高，该研究还证明了糖尿病困扰程度有临床上显著的改善。